September 2025 could be a make-or-break month for some biotech stocks, as the companies prepare to release critical clinical trial data.
The following are some of the biotech stocks to watch in September, with potential catalysts that may drive major market moves.
KALA BIO Inc. (KALA)
KALA is expected to release topline data from its CHASE trial of KPI-012 by the end of September 2025.
CHASE is a Phase 2b trial evaluating lead investigational topical biologic therapy, KPI-012, for the treatment of persistent corneal epithelial defect.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.